Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hairy cell leukemia.

M K Offermann, H M Golomb

    Current Problems in Cancer
    |January 1, 1984
    PubMed
    Summary

    Hairy cell leukemia (HCL) is a serious cancer where infections cause most deaths. Treatment involves splenectomy, chlorambucil, or radiation, with interferon showing early promise.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Late Relapse in Hodgkin's Disease: Report of Five Cases and a Review of the Literature.

    Leukemia & lymphoma·2016
    Same author

    Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2B.

    Leukemia & lymphoma·2016
    Same author

    Familial Lymphoproliferative Disorders with Chromosomal Fragile Site Analysis.

    Leukemia & lymphoma·2016
    Same author

    Low Dose Interferon Alfa-2B for the Induction of Remission of Hairy Cell Leukemia: A Multi-institutional Study of 49 Patients.

    Leukemia & lymphoma·2016
    Same author

    HDS: Establishment of a New Cell Line from a Hairy Cell Leukemia Patient with Resistance to Alpha-Interferon Therapy.

    Leukemia & lymphoma·2016
    Same author

    The Treatment of Hairy Cell Leukemia: A Review.

    Leukemia & lymphoma·2016

    Area of Science:

    • Hematology
    • Oncology
    • Immunology

    Background:

    • Hairy cell leukemia (HCL) presents a variable clinical course, ranging from indolent to rapidly fatal.
    • Immune system dysregulation significantly contributes to morbidity and mortality in HCL patients.
    • Infections, both pyogenic and nonpyogenic, are the primary cause of death in over 60% of HCL cases.

    Purpose of the Study:

    • To review the clinical course, complications, and evolving treatment strategies for hairy cell leukemia.
    • To highlight the significant impact of immune system alterations on patient outcomes.
    • To discuss current and emerging therapeutic options for managing HCL.

    Main Methods:

    • Review of existing literature on hairy cell leukemia.
    • Analysis of treatment outcomes for splenectomy, chlorambucil, and radiation therapy.
    • Evaluation of preliminary data on interferon as a treatment modality.

    Main Results:

    • Infections are the leading cause of death, responsible for over 60% of mortality.
    • Splenectomy is the primary treatment for symptomatic patients.
    • Chlorambucil demonstrates efficacy in managing disease progression post-splenectomy.
    • Radiation therapy offers local palliation for specific complications.
    • Interferon shows encouraging initial results, warranting further investigation.

    Conclusions:

    • Hairy cell leukemia management requires addressing immune complications, particularly infections.
    • Established treatments like splenectomy and chlorambucil remain crucial.
    • Radiation therapy has a role in palliative care.
    • Interferon presents a promising avenue for future HCL treatment research.

    Related Experiment Videos